Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central nervous method, conolidine modulates alternate molecular targets. A Science Innovations analyze located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://williamm753jlm4.buyoutblog.com/profile